Is it appropriate to continue eszopiclone (Lunesta) 2 mg orally at bedtime as needed for insomnia, with instructions to take only one dose and not double it because of central nervous system depression risk?

Eszopiclone 2 mg Dosing Instructions

Yes, this is correct—continue eszopiclone 2 mg at bedtime as needed for insomnia, and absolutely instruct the patient to never double-dose due to serious CNS depression risks.

Key Dosing Principles

The FDA label explicitly warns that eszopiclone should only be ingested immediately prior to going to bed and patients must be able to dedicate 8 hours to sleep 1. The instruction to avoid double-dosing is critical because:

• Dose-related adverse effects increase significantly with higher doses, particularly CNS depression 1
• The FDA specifically warns that doses exceeding the maximum recommended dose increase the risk of complex behaviors like sleep-driving, amnesia, and other dangerous neuropsychiatric symptoms 1
• Additive CNS-depressant effects occur when combined with other CNS depressants, and eszopiclone should never be taken with alcohol 1

Evidence Supporting 2 mg Dosing

Eszopiclone demonstrates efficacy for insomnia, though with important caveats:

• For the general adult population (ages 18-64): The 2016 American College of Physicians guideline found that eszopiclone improved short-term global and sleep outcomes compared to placebo, though absolute effect sizes were small (low- to moderate-strength evidence) 2, 3

• For elderly patients (≥65 years): The 2 mg dose effectively both induces and maintains sleep, while the 1 mg dose only reduces sleep latency 4, 5. The 2 mg dose also reduced daytime napping and improved quality of life measures including mood, physical health, and daytime alertness 5

• Meta-analysis data shows eszopiclone reduces sleep onset latency by 12 minutes, wake time after sleep onset by 17 minutes, and increases total sleep time by 28 minutes 6, 7

Critical Safety Warnings

The FDA label contains several black-box level warnings that must be communicated:

1. Complex sleep behaviors: Patients can engage in sleep-driving, preparing food, making phone calls, or having sex while not fully awake, with complete amnesia for these events 1. Strongly consider discontinuation if any sleep-driving episode occurs 1

2. CNS depression: Never combine with alcohol or other CNS depressants without dose adjustment 1

3. Next-day impairment: Caution patients against driving or operating machinery the day after taking eszopiclone, as impairment can persist 1

4. Psychiatric symptoms: Worsening depression, suicidal thoughts, hallucinations, and behavioral changes can occur unpredictably 1

5. Rare but serious reactions: Angioedema involving tongue, glottis, or larynx can be fatal—discontinue immediately if this occurs 1

Important Clinical Caveats

Long-term use concerns: The 2016 ACP guideline emphasizes that observational studies suggest hypnotic use is associated with increased risk for dementia, fractures, and major injury 2. The FDA approves pharmacologic therapy for short-term use (4-5 weeks), and patients should not continue for extended periods without re-evaluation 3. If insomnia doesn't remit within 7-10 days, evaluate for underlying psychiatric or medical illness 1.

PRN vs. nightly use: While you've prescribed it "PRN," the evidence base primarily supports nightly use. The "PRN" designation is reasonable for intermittent insomnia, but ensure the patient understands to take it only when needed and never more than once per night.

Most common adverse effects include unpleasant taste (18% vs placebo), dry mouth (4%), somnolence (4%), and dizziness (3%) 6, 7. These are generally well-tolerated but should be monitored.

Dose adjustments needed for:

• Severe hepatic impairment: reduce to 1 mg 1
• Elderly/debilitated patients: start at 1 mg 1
• Concurrent CYP3A4 inhibitors (ketoconazole, clarithromycin, ritonavir): reduce dose 1